Thermo-Fisher BRAHMS test falls short of NICE "impact evidence" needs
This article was originally published in Clinica
A highly promising innovative technology, Thermo-Fisher’s BRAHMS copeptin assay test for ruling out a suspected heart attack, has fallen short of full support for its use in the UK’s NHS, as a result of inadequate “clinical practice impact” evidence.
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.